Innovent Biologics Ratios and Metrics

Market cap in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2019 - 2016
Period Ending	Dec '25 Dec 4, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2019 - 2016
Market Capitalization	17,410	7,456	8,030	6,168	7,955	12,136	Upgrade
Market Cap Growth	132.14%	-7.15%	30.17%	-22.46%	-34.45%	216.45%	Upgrade
Enterprise Value	16,665	6,750	7,395	5,388	6,693	11,531	Upgrade
Last Close Price	9.95	4.36	4.50	3.84	5.10	8.05	Upgrade
PS Ratio	12.82	5.98	10.14	9.98	13.46	25.21	Upgrade
PB Ratio	10.16	4.30	5.02	4.24	5.56	11.04	Upgrade
P/TBV Ratio	11.24	4.40	5.04	4.25	5.57	11.04	Upgrade
P/FCF Ratio	101.18	175.32	-	-	-	-	Upgrade
P/OCF Ratio	80.64	43.78	425.78	-	-	-	Upgrade
EV/Sales Ratio	12.06	5.41	9.34	8.72	11.33	23.96	Upgrade
EV/EBITDA Ratio	108.94	2126.28	-	-	-	-	Upgrade
EV/FCF Ratio	96.84	158.73	-	-	-	-	Upgrade
Debt / Equity Ratio	0.23	0.22	0.29	0.30	0.24	0.14	Upgrade
Debt / EBITDA Ratio	2.54	50.93	-	-	-	-	Upgrade
Debt / FCF Ratio	2.33	8.81	-	-	-	-	Upgrade
Asset Turnover	0.52	0.45	0.33	0.27	0.30	0.40	Upgrade
Inventory Turnover	2.94	2.69	1.51	1.00	1.19	1.45	Upgrade
Quick Ratio	2.25	2.08	2.68	2.78	3.27	5.85	Upgrade
Current Ratio	2.61	2.35	3.00	3.29	3.79	6.37	Upgrade
Return on Equity (ROE)	8.43%	-0.74%	-8.84%	-20.70%	-28.56%	-14.75%	Upgrade
Return on Assets (ROA)	2.65%	-0.82%	-5.12%	-11.54%	-12.04%	-3.65%	Upgrade
Return on Capital (ROIC)	3.46%	-1.08%	-6.49%	-14.57%	-14.81%	-4.46%	Upgrade
Return on Capital Employed (ROCE)	5.00%	-1.60%	-9.70%	-22.20%	-20.50%	-5.40%	Upgrade
Earnings Yield	0.77%	-0.17%	-1.63%	-4.79%	-4.75%	-1.03%	Upgrade
FCF Yield	0.99%	0.57%	-1.54%	-6.19%	-5.38%	-0.82%	Upgrade
Buyback Yield / Dilution	-3.74%	-4.35%	-4.67%	-2.37%	-7.27%	-15.23%	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.